NO313489B1 - Anvendelse av neuraminidase i en fremgangsmåte for fremstilling av et farmasöytisk preparat - Google Patents
Anvendelse av neuraminidase i en fremgangsmåte for fremstilling av et farmasöytisk preparat Download PDFInfo
- Publication number
- NO313489B1 NO313489B1 NO19933628A NO933628A NO313489B1 NO 313489 B1 NO313489 B1 NO 313489B1 NO 19933628 A NO19933628 A NO 19933628A NO 933628 A NO933628 A NO 933628A NO 313489 B1 NO313489 B1 NO 313489B1
- Authority
- NO
- Norway
- Prior art keywords
- use according
- neuraminidase
- disease state
- herpes
- pharmaceutically acceptable
- Prior art date
Links
- 102000005348 Neuraminidase Human genes 0.000 title claims description 60
- 108010006232 Neuraminidase Proteins 0.000 title claims description 60
- 238000000034 method Methods 0.000 title description 3
- 238000002360 preparation method Methods 0.000 title description 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 40
- 201000010099 disease Diseases 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 15
- 208000007514 Herpes zoster Diseases 0.000 claims description 14
- 241001529453 unidentified herpesvirus Species 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- 206010067152 Oral herpes Diseases 0.000 claims description 8
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 7
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 7
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 7
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 7
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 5
- 201000006747 infectious mononucleosis Diseases 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims description 5
- 230000000737 periodic effect Effects 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 4
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 208000037357 HIV infectious disease Diseases 0.000 claims description 3
- 208000004898 Herpes Labialis Diseases 0.000 claims description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 32
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 15
- 241000700605 Viruses Species 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 12
- 230000028993 immune response Effects 0.000 description 11
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000003902 lesion Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 210000000822 natural killer cell Anatomy 0.000 description 8
- 241000700584 Simplexvirus Species 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 208000009889 Herpes Simplex Diseases 0.000 description 5
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 241000701027 Human herpesvirus 6 Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 208000001688 Herpes Genitalis Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 201000004946 genital herpes Diseases 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 238000003771 laboratory diagnosis Methods 0.000 description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101800000342 Glycoprotein C Proteins 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 206010019973 Herpes virus infection Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009830 antibody antigen interaction Effects 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001524178 Paenarthrobacter ureafaciens Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010061494 Rhinovirus infection Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000011421 subcutaneous treatment Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68207191A | 1991-04-09 | 1991-04-09 | |
| US86054692A | 1992-04-03 | 1992-04-03 | |
| PCT/US1992/002745 WO1992018158A1 (en) | 1991-04-09 | 1992-04-06 | Method and composition for the treatment of herpes related disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO933628D0 NO933628D0 (no) | 1993-10-08 |
| NO933628L NO933628L (no) | 1993-12-08 |
| NO313489B1 true NO313489B1 (no) | 2002-10-14 |
Family
ID=27102809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19933628A NO313489B1 (no) | 1991-04-09 | 1993-10-08 | Anvendelse av neuraminidase i en fremgangsmåte for fremstilling av et farmasöytisk preparat |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US5558863A (de) |
| EP (1) | EP0579765B1 (de) |
| JP (1) | JP3266254B2 (de) |
| AT (1) | ATE196424T1 (de) |
| AU (1) | AU662152B2 (de) |
| BR (1) | BR9205877A (de) |
| CA (1) | CA2108135C (de) |
| DE (1) | DE69231465T2 (de) |
| DK (1) | DK0579765T3 (de) |
| ES (1) | ES2151489T3 (de) |
| GR (1) | GR3035004T3 (de) |
| IE (1) | IE921141A1 (de) |
| IL (1) | IL101540A (de) |
| NO (1) | NO313489B1 (de) |
| WO (1) | WO1992018158A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001076621A2 (en) * | 2000-04-07 | 2001-10-18 | Kline Ellis L | Methods and compositions for treating neoplasms |
| JP5414366B2 (ja) * | 2009-05-29 | 2014-02-12 | 独立行政法人科学技術振興機構 | 疼痛治療剤 |
| AU2013323472B2 (en) * | 2012-09-28 | 2018-07-05 | Ellis KLINE | Glycosidase regimen for treatment of infectious disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI790483A (fi) * | 1978-02-16 | 1979-08-17 | Science Union & Cie | Foerfarande foer framstaellning av ett enzym av bakteriellt ursprung och farmaceutiska kompositioner innehaollande detsamma |
| JPS575916A (en) * | 1980-06-13 | 1982-01-12 | Teijin Ltd | Polyester fiber with soft touch and production of knitted and woven fabrics therefrom |
-
1992
- 1992-04-06 CA CA002108135A patent/CA2108135C/en not_active Expired - Fee Related
- 1992-04-06 JP JP51137692A patent/JP3266254B2/ja not_active Expired - Fee Related
- 1992-04-06 EP EP92911249A patent/EP0579765B1/de not_active Expired - Lifetime
- 1992-04-06 DE DE69231465T patent/DE69231465T2/de not_active Expired - Lifetime
- 1992-04-06 DK DK92911249T patent/DK0579765T3/da active
- 1992-04-06 BR BR9205877A patent/BR9205877A/pt not_active Application Discontinuation
- 1992-04-06 AT AT92911249T patent/ATE196424T1/de active
- 1992-04-06 WO PCT/US1992/002745 patent/WO1992018158A1/en active IP Right Grant
- 1992-04-06 AU AU19264/92A patent/AU662152B2/en not_active Ceased
- 1992-04-06 ES ES92911249T patent/ES2151489T3/es not_active Expired - Lifetime
- 1992-04-09 IE IE114192A patent/IE921141A1/en not_active IP Right Cessation
- 1992-04-09 IL IL10154092A patent/IL101540A/en not_active IP Right Cessation
-
1993
- 1993-10-08 NO NO19933628A patent/NO313489B1/no not_active IP Right Cessation
-
1995
- 1995-02-21 US US08/393,120 patent/US5558863A/en not_active Expired - Lifetime
-
1996
- 1996-09-19 US US08/716,053 patent/US5736133A/en not_active Expired - Lifetime
-
2000
- 2000-12-06 GR GR20000402695T patent/GR3035004T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK0579765T3 (da) | 2000-10-09 |
| AU662152B2 (en) | 1995-08-24 |
| WO1992018158A1 (en) | 1992-10-29 |
| ES2151489T3 (es) | 2001-01-01 |
| DE69231465T2 (de) | 2001-04-19 |
| NO933628L (no) | 1993-12-08 |
| EP0579765A4 (en) | 1994-08-24 |
| ATE196424T1 (de) | 2000-10-15 |
| IL101540A0 (en) | 1992-12-30 |
| IE921141A1 (en) | 1992-10-21 |
| DE69231465D1 (de) | 2000-10-26 |
| JPH06506698A (ja) | 1994-07-28 |
| CA2108135C (en) | 2008-03-11 |
| AU1926492A (en) | 1992-11-17 |
| GR3035004T3 (en) | 2001-03-30 |
| EP0579765B1 (de) | 2000-09-20 |
| US5736133A (en) | 1998-04-07 |
| IL101540A (en) | 1996-10-31 |
| JP3266254B2 (ja) | 2002-03-18 |
| EP0579765A1 (de) | 1994-01-26 |
| CA2108135A1 (en) | 1992-10-10 |
| NO933628D0 (no) | 1993-10-08 |
| US5558863A (en) | 1996-09-24 |
| BR9205877A (pt) | 1994-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Milligan et al. | Interferon-γ enhances resolution of herpes simplex virus type 2 infection of the murine genital tract | |
| JP2019537555A5 (de) | ||
| Nesburn et al. | A therapeutic vaccine that reduces recurrent herpes simplex virus type 1 corneal disease. | |
| JP2023123440A (ja) | 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物 | |
| Nesburn et al. | Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits | |
| Nesburn et al. | Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits | |
| Pizza et al. | Orally administered HSV-specific transfer factor (TF) prevents genital or labial herpes relapses | |
| Jose et al. | A cationic peptide, TAT-Cd0, inhibits herpes simplex virus type 1 ocular infection in vivo | |
| JPH06507386A (ja) | 治療用ペプチド | |
| NO313489B1 (no) | Anvendelse av neuraminidase i en fremgangsmåte for fremstilling av et farmasöytisk preparat | |
| Lausch et al. | Quantitation of purified monoclonal antibody needed to prevent HSV-1 induced stromal keratitis in mice | |
| Barrow et al. | An appraisal of the efficacy of the antiviral R 61837 in rhinovirus infections in human volunteers | |
| Phillpotts et al. | An effective dosage regimen for prophylaxis against rhinovirus infection by intranasal administration of HuIFN-α2 | |
| Hull et al. | Vaccination against herpesvirus infections | |
| Bravo et al. | Effect of antibody alone and combined with acyclovir on neonatal herpes simplex virus infection in guinea pigs | |
| IE83322B1 (en) | Method and composition for the treatment of herpes related disorders | |
| EP0080032A2 (de) | Pharmazeutische Zubereitung für die Behandlung von herpetischen Verletzungen | |
| KR100302994B1 (ko) | 약독화된비면역원성폭스바이러스또는파라폭스바이러스로부터멀티포텐트파라폭스면역유발인자의약제로서이용하는새로운적용 | |
| Fitzwilliam et al. | Experimental encephalitis caused by herpes simplex virus: comparison of treatment with tilorone hydrochloride and phosphonoacetic acid | |
| EP0335726A2 (de) | Verwendung von Thymopentin und Derivaten bei der Behandlung von HIV-Patienten | |
| Straus | The management of varicella and zoster infections | |
| Eis et al. | Pathogenesis of genital herpes simplex virus infection in mice: IV. Quantitative aspects of viral latency | |
| Georgiades et al. | Determinants of protection by human immune globulin against experimental herpes neonatorum | |
| Ashraf et al. | Management of Severe COVID-19 with Immunomodulators. Efficacy and Safety Issues | |
| WO2021238982A1 (zh) | 包含聚核苷酸的药物组合物及其用于预防或治疗covid-19的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |